CLDX Celldex Therapeutics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why CLDX matters now
Celldex Therapeutics, Inc. (CLDX) is a US stock in Healthcare. The latest InvestLog snapshot shows $38.98 with +0.05% on the session and $2.59B in market capitalization; recent performance reads 1-month +7.56% and YTD +19.40%.
The latest financial table shown here is Q1 2026, with revenue of $15.0K, net income of $-78.7M, and EPS of $-1.18. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -10.5%.
The latest indexable market news headline is "Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $48.00; recent insider activity includes Martin Samuel Bates filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.73
P/S
2631.51
EV/EBITDA
-7.58
DCF Value
$0.22
FCF Yield
-10.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-14287.9%
Operating Margin
-37694.6%
Net Margin
-34596.2%
ROE
-50.7%
ROA
-55.5%
ROIC
-67.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.0K | $-78.7M | $-1.18 |
| Q4 2025 | $75.0K | $-81.4M | $-1.23 |
| FY 2025 | $1.5M | $-258.8M | $-3.90 |
| Q3 2025 | $0.00 | $-67.0M | $-1.01 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$49.00
Target (Median)
$48.00
Target Range
$45.00 - $54.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.93
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.